Medicare will expand Part B coverage for certain home infusion pumps and their associated drugs on April 1, 2027. Eligibility depends on the drug's FDA-approved instructions and a qualified supplier.
The final home-health rule announced November 4 implements a provision of the Consolidated Appropriations Act, 2026. It is separate from the hospital outpatient and physician payment changes also announced this week.
Which treatments meet the new criteria
The expansion requires:
- The drug's FDA-approved prescribing information must say it should be administered by, or under the supervision of, a healthcare professional.
- A qualified home infusion therapy supplier must administer or supervise it safely and effectively in the patient's home.
- The FDA-approved instructions must call for at least 12 infusions per year, intravenously or under the skin, or at infusion rates that HHS determines require an external pump.
The final rule uses “at least 12 times per year” in place of the proposed once-a-month standard. It also allows an eligible healthcare professional to administer or supervise treatment within that professional's scope of practice.
What existing home-infusion coverage includes
Home infusion involves more than the medicine. Medicare's current coverage description separates equipment and supplies from the professional services needed to give certain drugs safely at home.
The equipment side can include pumps, IV poles, tubing and catheters. The services side can include nursing visits, training for a caregiver and monitoring the patient. A treatment plan therefore needs to account for the person providing the infusion as well as the device and medicine.
The November rule expands a specific part of the durable medical equipment definition. It does not establish that every infusion, drug or pump qualifies. The pictured devices are archival examples of infusion equipment, not a list of products approved under the new rule.
What patients could still pay
Under Original Medicare's current infusion-pump rules, a patient generally pays 20% of the Medicare-approved amount after meeting the Part B deductible, when the supplier accepts assignment. Medicare's home-infusion page also generally lists a 20% patient share for the professional services, equipment and supplies.
For an equipment charge with a Medicare-approved amount of $1,000, 20% is $200 after the deductible has been met. That is a calculation showing how coinsurance works, not a quoted pump price or an estimate of a complete course of treatment. Other insurance can change the patient's final share.
Ask whether the equipment will be rented or purchased. Medicare covers different equipment in different ways, and some items become the patient's property after a set number of rental payments. Also confirm that the supplier is enrolled in Medicare and accepts assignment. A supplier that does not accept assignment may charge more. Medicare already lists external pumps for deferoxamine to treat iron poisoning and morphine for cancer pain as examples of existing coverage. Those examples are not a new drug list.
Why a home-health benefit is a separate question
Medicare's home-health coverage page lists no patient charge for covered home-health services, while medical equipment generally carries 20% coinsurance after the Part B deductible. That difference can change the bill even when care takes place at home.
Home-health eligibility also requires a need for part-time or intermittent skilled services and homebound status. A clinician must assess the need, order the care and arrange it through a Medicare-certified home-health agency. Do not assume the home-health service price applies to every home infusion charge. Before home-health care starts, the agency should explain what Medicare will pay and identify uncovered items or services, with the expected patient charge. Medicare says the agency should provide an Advance Beneficiary Notice before giving supplies or services it will not cover.
Before arranging treatment under the April expansion, have the prescribing clinician and supplier check the exact drug, its labeled dosing schedule, the pump, professional services and expected patient charges. The new start date and frequency test alone do not determine an individual patient's coverage.
